Semaglutide
SURMOUNT-5
Novo Nordisk · Phase 3 · Completed · Enrollment 751
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| 15 mg or MTD - Tirzepatide | n/r | 87.7% | 71.7% | 55% |
| 2.4 mg or MTD - Semaglutide | n/r | 66.7% | 45% | 31.1% |
Not shown
Every selected arm is drawn.